Business
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
Final data from the METIS study anticipated in 2024 ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced that the final patient has
About this update from Novocure Limited
[{"type":"text","content":"\nFinal data from the METIS study anticipated in 2024 \n\n ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with brain metastases resulting from non-small cell lung cancer (NSCLC).\n\n“We are pleased to announce the completion of enrollment in the METIS study, our fourth pivotal study to complete enrollment in the last 17 months and our second study addressing non-small cell lung cancer,” said William Doyle, Novocure’s Executive Chairman. “Beginning with the top-line readout from the LUNAR study earlier this year, we expect a steady cadence of meaningful pivotal datasets through 2024. This is a transformational period for Novocure and, potentially, for the treatment of solid tumor cancers.”\n\nFollowing the completion of enrollment, patients will be followed for a minimum of 12 months.\n\nMETIS is a randomized, open-label pivotal study which was designed to enroll 270 adult patients with between 1 and 10 brain metastases resulting from NSCLC. Following SRS, patients were randomized to receive either TTFields therapy and supportive treatment or supportive treatment alone. The primary endpoint is time to first intracranial progression. Secondary endpoints include, but are not limited to, time to neurocognitive failure, overall survival, radiological response rate, time to second intracranial progression, quality of life and adverse events.\n\nAbout Brain Metastases\n\nMetastatic cancer is cancer that has spread from the place where it first started to another place in the body. In metastasis, cancer cells break away from where they first formed (the primary cancer), travel through the blood or lymph system, and form new tumors (the metastatic tumors) in other parts of the body. The exact incidence of brain metastases is unknown because no national cancer registry documents brain metastases, and estimates from scientific literature vary greatly based on the study methodology applied. It is estimated that between 100,000 and 240,000 new cases are diagnosed in the U.S. each year with brain metastases estimated to occur in between 10% to 40% of all cancer patients.\n\nBrain metastases are commonly treated with ...